Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5411]

Rolapitant reduces nausea and vomiting associated with cisplatin-based...

Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South...

Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy ( Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Africa )

New drug anamorelin shows improvement in appetite and body mass in non-small...

Prof David Currow - Flinders University, Adelaide, Australia

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia ( Prof David Currow - Flinders University, Adelaide, Australia )

Second-line afatinib significantly improves PFS in metastatic head and neck...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Second-line afatinib significantly improves PFS in metastatic head and neck cancer ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the...

Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )

Additional treatment options impact first-line treatment of mRCC: No

Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France

Additional treatment options impact first-line treatment of mRCC: No ( Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France )

Current treatment options in mRCC

Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA

Current treatment options in mRCC ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )

Discussion: Additional treatment options impact first-line treatment of mRCC

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

Discussion: Additional treatment options impact first-line treatment of mRCC ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )

Additional treatment options impact first-line treatment of mRCC: Yes

Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Additional treatment options impact first-line treatment of mRCC: Yes ( Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

What have we learned? Expert perspectives

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

What have we learned? Expert perspectives ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )

From clinical trial to clinical practice: Evidence from the real world

Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid...

From clinical trial to clinical practice: Evidence from the real world ( Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid, Madrid, Spain )

The evolving treatment landscape for HER2-positive metastatic breast cancer

Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium

The evolving treatment landscape for HER2-positive metastatic breast cancer ( Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium )

Navigating current treatment options for HER2-positive MBC: Patient journey 1

Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria

Navigating current treatment options for HER2-positive MBC: Patient journey 1 ( Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria )

More from ecancer